NVO: Novo-Nordisk A/S Company Profile & Statistics

Novo-Nordisk A/S Profile

About

Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

Info & Links

CEO

Maziar Mike Doustdar

Headquarters

Novo Alle 1
Bagsv�rd, G7 2880, DENMARK

Auditor

PricewaterhouseCoopers

Share holders

Employees

69,505

Novo-Nordisk A/S Statistics

Valuation Measures

Market Capitalization²

199.50B

Enterprise Value

215.32B

Enterprise Value/EBITDA(ttm)

9.50

Price to Earnings Ratio(ttm)

9.58

Price to Sales(ttm)

3.57

Price to Book(mrq)

5.69

Price to Cash(ytd)

7.99

Profitability

Gross Margin(ttm)

81.02%

Operating Margin(ttm)

37.23%

Profit Margin(ttm)

33.19%

Return on Equity(ttm)

68.91%

Return on Invested Capital(ttm)

39.43%

Return on Assets(ttm)

22.86%

Income Statement

Revenue(ttm)

46.79B

Revenue Per Share(ttm)

10.48

Gross Profit(ttm)

37.89B

EBITDA(ttm)³

22.66B

Net Income Available to Common(ttm)

15.51B

Diluted EPS(ttm)

3.47

Share Statistics

Beta (5Y Monthly)

0.73

52-Week Change

-28.89%

S&P 500 52-Week Change

26.78%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

4.46B

Dividend Yield

4.67%

Float⁴

4.46B

% Held by Insiders

0.07%

% Held by Institutions

11.54%

Balance Sheet

Total Cash(mrq)

5.09B

Total Cash Per Share(mrq)

1.14

Total Debt(mrq)

19.83B

Total Debt/Equity(mrq)

67.49%

Current Ratio(mrq)

0.80%

Quick Ratio(mrq)

0.57%

Book Value Per Share(mrq)

6.58

Cash Flow

Operating Cash Flow Per Share(ytd)

4.05

Free Cash Flow(ytd)

8.93B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

NVO

Novo-Nordisk A/S